“PsA rarely presents de novo; it usually evolves after a 3- to 10-year subclinical interval following cutaneous [psoriasis],” ...

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered. The treatment landscape for multiple myeloma (MM) ...

“ACO-SWITCH is a prospective study in adults with ATTR-CM,” wrote the researchers. “The study will determine the effects of ...

One in 5 adults with newly diagnosed moderate to severe plaque psoriasis maintained clear or almost-clear skin a full year ...

The FDA approved daraxonrasib (Rasonque), the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a ...

This FAQ covers the current prior authorization landscape, what's coming, and what health care stakeholders can expect. Q: ...

Medicare Part D changes, premium stabilization expiration, and a Bridge demonstration converge with rising GLP-1 demand and costs. Medicare Part D plans are running out of easy ways to absorb the cost ...

Respiratory therapists are another essential building block of a comprehensive care team for patients with bronchiectasis, said Robert A. Balk, MD, professor emeritus in the Department of Internal ...

Real-world primary care deployment achieved 93.6% successful screenings, with 1.56% requiring dilation and 27.2% referred to ophthalmology. Cost per diagnosed DR case reflected ~52% savings largely ...

Before nipaclaimab-aahu’s approval, there were no FDA-approved drugs specifically indicated for wAIHA. Treatment generally ...

The next episode in this series, 'Empowering Primary Care: Early Alzheimer's Detection and the Referral Pathway Challenge,' features the panelists advancing their conversation on Alzheimer's disease ...

Clinicians outline fragmented obesity and diabetes care models, insurance-driven prescribing, and early results from Medicare ...